Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a devastating disease with significant morbidity and mortality. There are many psychosocial and financial implications of this disease; however, little is known how this affects the treatment of PAH patients. A questionnaire-based prospective cohort study was...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/8/2/22 |
| _version_ | 1827715118502248448 |
|---|---|
| author | Scott A. Helgeson Divya Menon Haytham Helmi Charitha Vadlamudi John E. Moss Tonya K. Zeiger Charles D. Burger |
| author_facet | Scott A. Helgeson Divya Menon Haytham Helmi Charitha Vadlamudi John E. Moss Tonya K. Zeiger Charles D. Burger |
| author_sort | Scott A. Helgeson |
| collection | DOAJ |
| description | Pulmonary arterial hypertension (PAH) is a devastating disease with significant morbidity and mortality. There are many psychosocial and financial implications of this disease; however, little is known how this affects the treatment of PAH patients. A questionnaire-based prospective cohort study was performed on 106 PAH patients from a Pulmonary Hypertension Center and the Pulmonary Hypertension Association national conference in 2018. The demographic, treatment, psychosocial, employment, financial impact on treatment data was obtained. The majority of patients had cardiopulmonary symptoms despite treatment. The symptoms affected their social and work lives, with about one in three applying for disability because of their PAH. The majority of PAH patients had insurance coverage, but still noted a significant financial burden of the disease, with nearly a half who needed financial assistance to pay for their PAH medications. Thirty (28.3%; 95% CI, 20.6–37.5%) patients mentioned they changed their medication regimen, with some skipping doses outright (28 [26.4%; 95% CI, 19–35.6%]) in order to save money. PAH continues to cause significant psychosocial and financial burden on patients despite advances in medications. This impact ranged from dissatisfaction with quality of life, to unemployment, to altering their medication regimen to save money. |
| first_indexed | 2024-03-10T19:12:00Z |
| format | Article |
| id | doaj.art-4d551728e32b42ca8e3e4c85d508f55c |
| institution | Directory Open Access Journal |
| issn | 2079-9721 |
| language | English |
| last_indexed | 2024-03-10T19:12:00Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj.art-4d551728e32b42ca8e3e4c85d508f55c2023-11-20T03:43:22ZengMDPI AGDiseases2079-97212020-06-01822210.3390/diseases8020022Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial HypertensionScott A. Helgeson0Divya Menon1Haytham Helmi2Charitha Vadlamudi3John E. Moss4Tonya K. Zeiger5Charles D. Burger6Department of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Pulmonary and Critical Care Medicine, Tufts Medical Center, Boston, MA 02111, USADepartment of Emergency Medicine, University of Florida, Jacksonville, FL 32224, USADepartment of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL 32224, USAPulmonary arterial hypertension (PAH) is a devastating disease with significant morbidity and mortality. There are many psychosocial and financial implications of this disease; however, little is known how this affects the treatment of PAH patients. A questionnaire-based prospective cohort study was performed on 106 PAH patients from a Pulmonary Hypertension Center and the Pulmonary Hypertension Association national conference in 2018. The demographic, treatment, psychosocial, employment, financial impact on treatment data was obtained. The majority of patients had cardiopulmonary symptoms despite treatment. The symptoms affected their social and work lives, with about one in three applying for disability because of their PAH. The majority of PAH patients had insurance coverage, but still noted a significant financial burden of the disease, with nearly a half who needed financial assistance to pay for their PAH medications. Thirty (28.3%; 95% CI, 20.6–37.5%) patients mentioned they changed their medication regimen, with some skipping doses outright (28 [26.4%; 95% CI, 19–35.6%]) in order to save money. PAH continues to cause significant psychosocial and financial burden on patients despite advances in medications. This impact ranged from dissatisfaction with quality of life, to unemployment, to altering their medication regimen to save money.https://www.mdpi.com/2079-9721/8/2/22pulmonary hypertensionpsychosocialfinancialtreatment |
| spellingShingle | Scott A. Helgeson Divya Menon Haytham Helmi Charitha Vadlamudi John E. Moss Tonya K. Zeiger Charles D. Burger Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension Diseases pulmonary hypertension psychosocial financial treatment |
| title | Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension |
| title_full | Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension |
| title_fullStr | Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension |
| title_full_unstemmed | Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension |
| title_short | Psychosocial and Financial Burden of Therapy in USA Patients with Pulmonary Arterial Hypertension |
| title_sort | psychosocial and financial burden of therapy in usa patients with pulmonary arterial hypertension |
| topic | pulmonary hypertension psychosocial financial treatment |
| url | https://www.mdpi.com/2079-9721/8/2/22 |
| work_keys_str_mv | AT scottahelgeson psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT divyamenon psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT haythamhelmi psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT charithavadlamudi psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT johnemoss psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT tonyakzeiger psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension AT charlesdburger psychosocialandfinancialburdenoftherapyinusapatientswithpulmonaryarterialhypertension |